The new release of Quantib Prostate is an AI-based software solution that is said to improve the MRI prostate reporting workflow and its output for radiologists and urologists
RadNet has secured clearance from the US Food and Drug Administration (FDA) for the third-generation rollout of its Quantib Prostate MRI artificial intelligence (AI) software.
The third-generation release of the software is expected to bolster the offering with new and updated tools.
Quantib Prostate software for MRI reading support was initially launched in the US. In 2021, it was given a class IIb CE marking in Europe.
The new release of Quantib Prostate is an AI-based software solution that is said to improve the MRI prostate reporting workflow and its output for urologists and radiologists.
With the FDA 510(k) special clearance to Quantib Prostate 3.0, a major upgrade to the latest Quantib Prostate 2.1 release has been introduced, said RadNet.
Quantib Prostate 3.0 offers a portfolio of tools to enhance reporting quality and speed.
The tools include PSA density calculation, AI-based segmentations and volumetry, precise registration and movement correction, one-click segmentation of lesion candidates, and PI-RADS scoring support.
Besides, it offers standardised reporting to enable easy and comprehensive communication of results.
Furthermore, Quantib Prostate 3.0 will include an automated drawing of the lesions on the PI-RADS sector map, enhanced prostate and sub-region segmentation algorithm and other functionalities to improve the user experience.
Quantib CEO Arthur Uiterweer said: “We are excited to present this update of Quantib Prostate, which enables us to continue to support our customers with the newest developments and improved AI algorithm performance.
“We strive to regularly and continuously improve our software in order to support radiologists and urologists in the best possible way.”
A fully-owned subsidiary of RadNet, Quantib offers AI radiology solutions to allow faster and more accurate diagnosis by rapidly identifying abnormalities and promote adequate and timely patient care.